| Codiak Bio’s IPO Brings In $82M as Exosome Clinical Trials Begin | Frank Vinluan | 10/14/20 | Boston |
| Roche Enlists Dyno to Bring AI to Next-Generation Liver, CNS Gene Therapies | Frank Vinluan | 10/14/20 | Boston |
| Biogen’s AdComm Meeting Will Test FDA’s “Substantial Evidence” Flexibility | Sue Sutter | 10/08/20 | Boston |
| FDA Lifts Solid Bio Clinical Hold, Duchenne Study Cleared to Resume | Frank Vinluan | 10/01/20 | Boston |
| Bio Roundup: COVID-19 Pact, Gavreto Approval, Generative Biology & More | Frank Vinluan | 09/11/20 | National |
| Now Closer to Clinical Trials, Codiak BioSciences Refiles IPO Plans | Frank Vinluan | 09/10/20 | Boston |
| Bio Roundup: Seres Soars, MesoBlast Vote, Duchenne Decision & More | Frank Vinluan | 08/14/20 | National |
| With FDA Nod, NS Pharma Duchenne Drug Becomes Sarepta Competitor | Frank Vinluan | 08/12/20 | New York |
| Vesigen Nabs $28M to Wrap “ARMMS” Around Large Molecule Drug Delivery | Frank Vinluan | 07/22/20 | Boston |
| Bio Roundup: Gilead’s Pionyr Grab, Relay to IPO, Unicorn Sana & More | Sarah de Crescenzo | 06/26/20 | National |
| Sarepta Inks Codiak Deal to Explore Combining Exosomes, Muscle Meds | Sarah de Crescenzo | 06/22/20 | Boston |
| Biotech Roundup: BIO on Racism, AbbVie Antibodies, IPO Surge & More | Sarah de Crescenzo | 06/12/20 | National |
| Bio Roundup: FDA Dings BMS, Genfit’s Fall, Alexion’s Activist & More | Sarah de Crescenzo | 05/15/20 | National |
| Bio Roundup: Acquisitive Alexion, CRISPR on COVID, C. diff Success & More | Frank Vinluan | 05/08/20 | National |
| Bio Roundup: Coronavirus Concerns, Sarepta’s CRL, Eye Drug OK’d & More | Sarah de Crescenzo | 01/24/20 | National |
| FDA Flags Risk of Infection, Kidney Damage for Sarepta Duchenne Drugs | Frank Vinluan | 01/22/20 | Boston |
| Roche Puts Up Historic $1.15B for Sarepta Duchenne Gene Therapy Deal | Sarah de Crescenzo | 12/23/19 | Boston |
| Wave Stock Crashes After Decision to Halt Duchenne Drug Studies | Melissa Fassbender | 12/16/19 | Boston |
| Bio Roundup: Sarepta’s Approval, Merck M&A, Drug Price Bill & More | Frank Vinluan | 12/13/19 | National |
| In an About-Face, FDA Approves Second Sarepta Muscular Dystrophy Drug | Sarah de Crescenzo | 12/13/19 | Boston |
| Perceptive Unveils New $210M Fund to Invest in Early-Stage Biotechs | Frank Vinluan | 12/10/19 | New York |
| Biotech Roundup: Gottlieb v. Juul, Solid Slumps, Avidity Gets $100M & More | Sarah de Crescenzo | 11/15/19 | National |
| Bio Roundup: PARP Progress, A New Commish, IPO-Palooza & More | Ben Fidler | 10/04/19 | National |
| Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More | Frank Vinluan | 08/23/19 | National |
| FDA Rejects Sarepta’s Second Duchenne Drug, Citing Safety Concerns | Ben Fidler | 08/19/19 | Boston |
| Four New Drugs Are Around the Corner. Here’s What You Need to Know. | Ben Fidler | 08/15/19 | National |
| Bio Roundup: Surprise News, a Gene Therapy Mess & a CAR-T Step | Ben Fidler | 08/09/19 | National |
| Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More | Frank Vinluan | 08/02/19 | National |
| Amicus Offers First Look At Gene Therapy Work With Batten’s Data | Ben Fidler | 08/01/19 | New York |
| Duchenne Advocates Start Casimir, Aiming to Capture Missing Data | Ben Fidler | 07/26/19 | Boston |
